Golimumab for the treatment of psoriatic arthritis

This guidance was developed using the single technology appraisal process
Golimumab for the treatment of psoriatic arthritis

Ordering information

You can download the following documents from www.nice.org.uk/guidance/TA220

- The NICE guidance (this document).
- A quick reference guide – the recommendations.
- ‘Understanding NICE guidance’ – a summary for patients and carers.
- Details of all the evidence that was looked at and other background information.

For printed copies of the quick reference guide or ‘Understanding NICE guidance’, phone NICE publications on 0845 003 7783 or email publications@nice.org.uk and quote:

- N2519 (quick reference guide)
- N2520 (‘Understanding NICE guidance’).

This guidance represents the view of NICE, which was arrived at after careful consideration of the evidence available. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Implementation of this guidance is the responsibility of local commissioners and/or providers. Commissioners and providers are reminded that it is their responsibility to implement the guidance, in their local context, in light of their duties to avoid unlawful discrimination and to have regard to promoting equality of opportunity. Nothing in this guidance should be interpreted in a way which would be inconsistent with compliance with those duties.

National Institute for Health and Clinical Excellence
MidCity Place
71 High Holborn
London WC1V 6NA

www.nice.org.uk

© National Institute for Health and Clinical Excellence, 2011. All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE.
Contents

1  Guidance  4
2  The technology  4
3  The manufacturer’s submission  5
4  Consideration of the evidence  13
5  Implementation  27
6  Recommendation for further research  28
7  Related NICE guidance  28
8  Review of guidance  29

Appendix A: Appraisal Committee members and NICE project team  30
Appendix B: Sources of evidence considered by the Committee  34

NHS Evidence has accredited the process used by the Centre for Health Technology Evaluation at NICE to produce guidance. Accreditation is valid for 3 years from April 2010 and is applicable to guidance produced using the processes described in NICE’s ‘Guide to the single technology appraisal process’ (2009). More information on accreditation can be viewed at www.evidence.nhs.uk
1 Guidance

1.1 Golimumab is recommended as an option for the treatment of active and progressive psoriatic arthritis in adults only if:

- it is used as described for other tumour necrosis factor (TNF) inhibitor treatments in ‘Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis’ (NICE technology appraisal guidance 199), and
- the manufacturer provides the 100 mg dose of golimumab at the same cost as the 50 mg dose.

1.2 When using the Psoriatic Arthritis Response Criteria (PsARC; as set out in NICE technology appraisal guidance 199), healthcare professionals should take into account any physical, sensory or learning disabilities, or communication difficulties that could affect a person’s responses to components of the PsARC and make any adjustments they consider appropriate.

2 The technology

2.1 Golimumab (Simponi, Schering-Plough/Centocor) is a human monoclonal antibody that prevents the binding of tumour necrosis factor (TNF) to its receptors, thereby neutralising its activity. Golimumab has a marketing authorisation for the treatment of active and progressive psoriatic arthritis (alone or in combination with methotrexate) in adults when the response to previous disease-modifying antirheumatic drug (DMARD) therapy has been inadequate. The summary of product characteristics (SPC) notes that golimumab has also been shown to improve physical function in this population.

2.2 Golimumab is contraindicated in people with moderate to severe heart failure, hereditary problems of fructose intolerance, active tuberculosis and other severe infections. Before initiating therapy,
physicians should evaluate people for prior evidence of hepatitis B virus infection, and both active and inactive (latent) tuberculosis infection. The SPC states that the needle cover on the pre-filled golimumab injection pen contains latex and therefore may cause allergic reactions in people with latex sensitivity. The SPC reports that the most common adverse reactions are upper respiratory tract infections, including nasopharyngitis, pharyngitis, laryngitis and rhinitis. For full details of adverse effects, contraindications, special warnings and precautions for use, see the SPC.

2.3 Golimumab is injected subcutaneously via a pre-filled injection pen. The recommended dose is 50 mg given once a month, on the same date each month. The SPC states that in people who weigh more than 100 kg whose psoriatic arthritis does not show an adequate clinical response after three or four doses, the dose of golimumab may be increased to 100 mg once a month. The cost of golimumab is £774.58 for a 50 mg pre-filled injection pen (excluding VAT, ‘MIMS’ February 2011 edition), which is equivalent to an annual cost of £9294.96 (based on the 50 mg dose). Costs may vary in different settings because of negotiated procurement discounts.

2.4 The manufacturer of golimumab has agreed a patient access scheme with the Department of Health, in which the 100 mg dose of golimumab will be available to the NHS at the same cost as the 50 mg dose. The Department of Health considered that this patient access scheme does not constitute an excessive administrative burden on the NHS.

3 The manufacturer’s submission

The Appraisal Committee (appendix A) considered evidence submitted by the manufacturer of golimumab and a review of this submission by the Evidence Review Group (ERG; appendix B).
The main clinical effectiveness data were derived from a single phase III randomised controlled trial (RCT) – GO-REVEAL. The trial compared golimumab with placebo for the treatment of active and progressive psoriatic arthritis in people who had symptoms despite the use of current or previous DMARDs or non-steroidal anti-inflammatory drugs. Of the 405 trial participants, 113 were randomised to placebo, 146 were randomised to a 50 mg dose of golimumab and 146 were randomised to a 100 mg dose of golimumab. Randomisation was maintained for 24 weeks. Upward titration was allowed at week 16, such that the participants in the placebo group could switch to 50 mg golimumab and those in the 50 mg golimumab group could have their dose increased to 100 mg if their disease had failed to respond. In the placebo group 50% of participants crossed over to golimumab 50 mg treatment and in the golimumab 50 mg group 20% crossed over to golimumab 100 mg treatment. Outcomes were assessed at 14 and 24 weeks.

The primary outcomes in GO-REVEAL were American College of Rheumatology (ACR) 20 response at week 14 and the change from baseline in the psoriatic arthritis modified van der Heijde-Sharp (vdH-S) score at week 24. Secondary outcomes included ACR 20 response at week 24, Psoriatic Arthritis Response Criteria (PsARC) response at weeks 14 and 24, and Psoriasis Area and Severity Index (PASI) 75 improvement at week 14 in participants with psoriasis that affected 3% or more of their body surface area at baseline. Physical functional status was measured by Health Assessment Questionnaire (HAQ) score at week 24. Health-related quality of life was measured by the Short Form 36 Health Survey (SF-36) at week 14.

The week 14 results of GO-REVEAL indicated that, compared with placebo, golimumab showed a statistically significant improvement in joint disease. An ACR 20 response was seen in 50.7% of participants in the 50 mg treatment arm compared with 8.8% in the
placebo arm (relative risk [RR] 5.727, 95% confidence interval [CI] 3.24 to 10.56). A PsARC response was seen in 73.3% of participants in the 50 mg treatment arm compared with 21.2% in the placebo arm (RR 3.451, 95% CI 2.46 to 4.87). Golimumab also showed a statistically significant improvement in skin disease as measured by PASI 75 at both 14 and 24 weeks. A PASI 75 response was seen in 40.4% of participants in the 50 mg treatment arm compared with 2.5% in the placebo arm (RR 15.945, 95% CI 4.62 to 59.11) at 14 weeks, and in 55.9% of participants in the 50 mg treatment arm compared with 1.4% in the placebo arm (RR 40.794, 95% CI 7.86 to 232.88) at 24 weeks. There was also a statistically significant improvement in functional status (HAQ) at 24 weeks. A mean HAQ score change from baseline of 0.33 (standard deviation [SD] 0.55, p < 0.001) was observed in the golimumab 50 mg arm compared with −0.01 (SD 0.49) in the placebo arm. Data on HAQ score change from baseline were not available for the 14-week time point.

3.4 The manufacturer reported that golimumab 50 mg produced a statistically significant reduction from baseline in vdH-S score of 0.16 (p = 0.01) at 24 weeks compared with placebo. The reduction from baseline in vdH-S score was not statistically significant in the golimumab 100 mg group (p = 0.09). The manufacturer did not report vdH-S scores at the 14 week time point.

3.5 The Evidence Review Group (ERG) reported that the main limitation of the efficacy evaluation of golimumab was that the analyses of efficacy outcomes were restricted to the GO-REVEAL trial, which had a limited sample size and was of limited duration (see section 3.1).

3.6 The manufacturer stated that the most frequently reported adverse events associated with golimumab therapy were infections and infestations, including upper respiratory tract infections and nasopharyngitis. The manufacturer reported that the safety profile
of golimumab was comparable to that of the other TNF inhibitors adalimumab, etanercept and infliximab.

3.7 The ERG reported concerns about the adverse event data presented for golimumab. It noted that no long-term adverse event data had been presented, and that in its original submission the manufacturer had not included adverse event data on golimumab from controlled studies of its use in other conditions such as rheumatoid arthritis or ankylosing spondylitis. The ERG reported that the manufacturer’s conclusion that golimumab has a safety profile comparable to that of the other TNF inhibitors may be premature.

3.8 Following consultation on the Appraisal Consultation Document, the manufacturer submitted evidence on the long-term safety of golimumab. These data included 104-week results from the GO-REVEAL extension study in addition to 52- and 104-week safety data in trial participants with psoriatic arthritis, rheumatoid arthritis and ankylosing spondylitis who had received treatment with golimumab across all of the original phase III studies. These data were marked as confidential and therefore cannot be reported.

3.9 In the absence of head-to-head comparisons between golimumab and the other TNF inhibitors, the manufacturer conducted a mixed treatment comparison. The mixed treatment comparison included seven trials: the GO-REVEAL trial (golimumab versus placebo); two RCTs comparing etanercept with placebo (Mease 2000 and Mease 2004); two RCTs comparing infliximab with placebo (IMPACT and IMPACT 2); and two RCTs comparing adalimumab with placebo (ADEPT and Genovese 2007). All of the TNF inhibitors have marketing authorisations for the treatment of active and progressive psoriatic arthritis that has responded inadequately to previous DMARDs.
3.10 The trials included in the mixed treatment comparison were similar in terms of joint disease severity at baseline (for example, mean tender joint count and mean swollen joint count). There were differences, however, in the proportions of trial participants who could be evaluated for psoriasis endpoints at baseline. Most participants had received treatment with one prior DMARD, although no trial specified non-response to at least two DMARDs.

3.11 The outcomes included in the mixed treatment comparison analyses were PsARC response, change in HAQ score given PsARC response to treatment, change in HAQ score given no PsARC response, and change in PASI in people with psoriasis that affected 3% or more of their body surface area at baseline. The manufacturer selected absolute changes as the main outcomes, stating that these were the most appropriate outcomes for economic modelling. No analysis of the ACR outcomes was included in the mixed treatment comparison.

3.12 The results of the mixed treatment comparison indicated that of the four TNF inhibitors, golimumab was associated with the third highest PsARC response and absolute change in PASI from baseline. Of the four TNF inhibitors, golimumab had the lowest HAQ score change from baseline, both in people whose disease responded to treatment based on PsARC score and in those whose disease did not respond. The numerical values for each outcome derived from the mixed treatment comparison were marked as confidential and therefore cannot be reported.

3.13 The ERG reported that the network of trials included in the mixed treatment comparison was appropriately constructed, but that there were differences among the trial populations in disease severity and number of previously tried DMARDs (with many participants having received only one previous DMARD). The ERG commented that the trial populations were not precisely representative of the population with active and progressive psoriatic arthritis for whom
TNF inhibitors are recommended in current British Society for Rheumatology guidelines and in ‘Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis’ (NICE technology appraisal guidance 199 [TA199]).

3.14 The manufacturer developed its own economic evaluation, which comprised a patient cohort model. The model compared the effects of treatment with golimumab (50 mg) in adults with active and progressive psoriatic arthritis whose disease had responded inadequately to DMARDs with the effects of treatment with infliximab, adalimumab and etanercept and with palliative care. All people entered the model with the same baseline characteristics as participants in the GO-REVEAL trial and left the model at death, irrespective of the treatment regimen. The model used a 12-week cycle for the first two cycles and annual cycles thereafter. The model captured response to treatment using HAQ score (conditional on PsARC response) as the arthritis measure and PASI score as the psoriasis measure. If there was no response to treatment at 12 weeks (according to PsARC), treatment was discontinued. The price year used for costs was not reported in the manufacturer’s submission. Costs and benefits were discounted at 3.5% per annum over 40 years.

3.15 The manufacturer reported that estimates of treatment effectiveness – including PsARC response, HAQ score changes from baseline for people whose disease had responded to treatment according to PsARC at 12 weeks, HAQ score changes from baseline for those whose disease had not responded to treatment according to PsARC at 12 weeks, and PASI change from baseline in people with measurable psoriasis – were derived from the mixed treatment comparison.

3.16 The model assumed that people who continue treatment with a TNF inhibitor maintain their initial improvement in HAQ score. The same ongoing rate of withdrawal from treatment was used for all
the TNF inhibitors (16.5% per annum) and represented withdrawal because of treatment failure or adverse events.

3.17 The manufacturer combined data from IMPACT2 (a study of infliximab) and GO-REVEAL using the ‘Gray’ algorithm to estimate utility values. The Gray algorithm converts Short Form 36 (SF-36) data to EuroQol (EQ-5D) estimates and then to utilities. The disutility of adverse events was not modelled.

3.18 The manufacturer reported that resource use associated with treatment, administration and monitoring of infliximab, etanercept and adalimumab was taken from the Assessment Group’s model for TA199. In the patient access scheme (as described in section 2.4) the manufacturer provides the 100 mg dose of golimumab at the same cost as the 50 mg dose. Therefore, only the cost of the 50 mg dose of golimumab (£774.58) was included in the model. The model contained an additional 4 hours of staff nurse costs for training people to self-administer subcutaneous TNF inhibitors. The costs of infliximab were initially calculated on the assumption that vial sharing was allowed (using an average of 3.5 vials per infusion, although this assumption was later removed following a request for clarification from the ERG). The costs associated with adverse events were not included.

3.19 The manufacturer revised its original base-case estimates in response to a request from the ERG for clarification about the way utilities were calculated and for the removal of the infliximab vial sharing assumption. The revised base-case results produced total costs, total quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICERs, pairwise comparisons with palliative care) as follows:

- palliative care: total costs of £62,224 and total QALYs of 6.61
- adalimumab: total costs of £86,410 and total QALYs of 7.89, resulting in an ICER of £18,824 per QALY gained
golimumab: total costs of £94,151 and total QALYs of 8.21, resulting in an ICER of £19,993 per QALY gained
etanercept: total costs of £94,578 and total QALYs of 8.49, resulting in an ICER of £17,177 per QALY gained
infliximab: total costs of £106,620 and total QALYs of 8.49, resulting in an ICER of £23,578 per QALY gained.

3.20 The ERG reported that the manufacturer had not provided an incremental analysis in which dominated and extendedly dominated options were excluded. An option is 'dominated' if there is another option that is less costly and more effective. An option is 'extendedly dominated' when its ICER is higher than that of the next, more effective, option when compared with a common baseline (that is, it is dominated by a combination of two other alternatives). The ERG recalculated the manufacturer’s base-case results by incrementally comparing each treatment with the next, more effective, option and excluding those that were extendedly dominated. The recalculated base-case results showed that both adalimumab and golimumab were extendedly dominated by a combination of etanercept and palliative care. Etanercept in comparison with palliative care was associated with an incremental cost of £32,354 and an incremental QALY gain of 1.88, resulting in an ICER of £17,209. Infliximab was dominated by etanercept.

3.21 The manufacturer conducted two subgroup analyses: one of the population with 'predominantly' rheumatic disease and one of the population with 'significant' psoriasis. The ERG recalculated the results of these analyses as described in section 3.20. The results of the recalculated subgroup analyses show adalimumab and golimumab to be extendedly dominated by a combination of etanercept and palliative care. Etanercept in comparison with palliative care was associated with an incremental cost of £34,492 and an incremental QALY gain of 2.21, resulting in an ICER of £15,607 per QALY gained in the rheumatic disease subgroup. In
the psoriasis subgroup, etanercept in comparison with palliative care was associated with an incremental cost of £31,564 and an incremental QALY gain of 2.25, resulting in an ICER of £14,028 per QALY gained. Infliximab was dominated by etanercept in the rheumatic disease subgroup, and was associated with an incremental cost of £5702 and an incremental QALY gain of 0.01, resulting in an ICER of £570,200 per QALY gained in comparison with etanercept in the psoriasis subgroup.

3.22 The ERG commented that the model structure was reasonable. The ERG stated that the inclusion of costs to cover time for training in self-injection may have been unnecessary, but reported that all other included costs were appropriate. The ERG considered that it may have been appropriate to account for the possibility of dose escalation to 100 mg (as per the marketing authorisation; see section 2.3). The ERG reported that the subgroup analyses were appropriate.

3.23 Full details of all the evidence are in the manufacturer’s submission and the ERG report, which are available from www.nice.org.uk/guidance/TA220

4 Consideration of the evidence

4.1 The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of golimumab, having considered evidence on the nature of psoriatic arthritis and the value placed on the benefits of golimumab by people with the condition, those who represent them, and clinical specialists. It also took into account the effective use of NHS resources and the impact of the patient access scheme (see section 2.4).

4.2 The Committee understood that psoriatic arthritis can cause significant distress and psychological impact on the person’s life, employment and social activities. The Committee heard from a patient expert that TNF inhibitors are valued options for the
treatment of psoriatic arthritis and have a positive impact on quality of life. It understood that people with the condition may prefer the option of a treatment that is self-injectable and/or has a longer retreatment interval. The Committee understood that people value having a choice of TNF inhibitors and that another treatment option will always be welcome.

4.3 The Committee considered current clinical practice for the treatment of psoriatic arthritis. It understood that TA199 recommends adalimumab, etanercept and infliximab for the treatment of psoriatic arthritis in people who have peripheral arthritis with three or more tender joints and three or more swollen joints, and when the psoriatic arthritis has not responded to adequate trials of at least two standard DMARDs (administered either individually or in combination). The Committee also noted that TA199 specifies that treatment should be with the least expensive drug, taking into account drug administration costs, required dose and product price per dose. It heard from the clinical specialists that they considered there to be little demonstrable difference between the TNF inhibitors in terms of their clinical effectiveness. The clinical experts did, however, note slight differences among the TNF inhibitors in TA199 with regard to the subjective reduction in response to treatment in the skin and joint components of the disease. The Committee heard from the commissioning expert that subtle differences in cost and administration, particularly with regard to dose escalation (as included in the marketing authorisation for infliximab) and hospitalisation, can make a big cost difference. The Committee concluded that adalimumab, etanercept and infliximab were the appropriate comparators for golimumab.

4.4 The Committee heard from the clinical specialists and the patient expert that people often prefer a less frequent dosing schedule; that is, a longer time period between treatments. However, the
Committee noted that the longer retreatment interval associated with golimumab could potentially result in more discomfort because of waning efficacy before retreatment. It understood that people with psoriatic arthritis and their clinicians may therefore value the once-monthly, self-injectable administration of golimumab. The Committee concluded that golimumab could, on balance, be a valued additional treatment option for people with psoriatic arthritis.

4.5 The Committee considered the evidence on the clinical effectiveness of golimumab. It understood that the main clinical effectiveness data were derived from a single phase III RCT. The Committee noted statistically significant outcomes for the 50 mg dose compared with placebo in terms of improvements in joint disease, skin disease and functional status (see sections 3.3 and 3.4). The Committee concluded that golimumab was clinically effective compared with placebo.

4.6 The Committee discussed the 100 mg dose of golimumab, which may be considered for people who weigh more than 100 kg and whose psoriatic arthritis has not responded after three or four doses of golimumab (as stated in the SPC). It noted that neither the 100 mg arm nor dose escalation to 100 mg in the 50 mg arm in the GO-REVEAL trial was limited to people who weighed more than 100 kg, and therefore the trial population did not reflect the population in the marketing authorisation for the 100 mg dose. The Committee heard from clinical specialists that they would be more likely to select a different TNF inhibitor than to increase the dose if the 50 mg dose of golimumab failed to produce a response. The Committee concluded that it was uncertain of the extent to which the 100 mg dose would be used in clinical practice.

4.7 The Committee noted that there had been no head-to-head trials of golimumab and any of the other TNF inhibitors, and that, as a result, the manufacturer had conducted a mixed treatment comparison. The Committee recognised the limitations of mixed
treatment comparisons and was aware that the associated results would need to be interpreted with caution. It also noted the manufacturer’s reservations about mixed treatment comparisons and the uncertainty associated with the use of such methodologies, but noted that no alternative methods or data had been provided.

Following the consultation on the Appraisal Consultation Document, the manufacturer suggested the removal of the Mease 2000 results (for etanercept) from the mixed treatment comparison, because this trial did not disaggregate HAQ scores in the same way as other trials, and showed better results for etanercept than Mease 2004 (the larger etanercept trial). The Committee had misgivings about the selective removal of individual trials, but heard from the ERG that extracting the Mease 2000 study from the mixed treatment comparison had little effect on the results. The Committee agreed it would bear this in mind when considering the results of the mixed treatment comparison.

4.8 The Committee carefully considered the results of the mixed treatment comparison. It noted that for PsARC response and absolute change in PASI from baseline, the results showed that golimumab was generally equivalent to the other TNF inhibitors. However, it also noted that golimumab had the lowest HAQ score change from baseline (both in participants whose disease responded to treatment based on PsARC score and those whose disease did not respond based on PsARC score) compared with the other TNF inhibitors.

4.9 The Committee further discussed the HAQ results from the mixed treatment comparison. The Committee understood from the clinical specialists and the patient expert that pain and disability caused by arthritis (as captured by HAQ score and reflected in the manufacturer’s economic model) often have a significant impact on the person’s quality of life. The Committee was concerned that, out of the four TNF inhibitors that were compared, golimumab had the
lowest HAQ score change from baseline and that this might indicate inferiority of its anti-arthritic activity (see section 3.12); however, the Committee was also aware of the limitations of the mixed treatment comparison methodology. Therefore the Committee also considered the radiographic progression data, which, together with the change in HAQ score, could be used to assess the effect of a treatment on disease progression. The Committee noted the statistically significant reduction from baseline in vdH-S score (a measure of radiographic progression) for golimumab compared with placebo at 24 weeks (−0.16 for 50 mg golimumab compared with 0.27 for placebo, p = 0.01; see section 3.4). It noted that the change from baseline in vdH-S score at week 24 for golimumab was less than that for infliximab (−0.70 for 5 mg/kg infliximab compared with 0.82 for placebo, p < 0.001), which was the other TNF inhibitor for which radiographic progression was measured by vdH-S score in the trials included in the mixed treatment comparison. The Committee was aware, however, that this difference may be due to differences in the trial populations, as reflected by the respective changes from baseline with placebo. The Committee also understood that the absolute differences between the two changes from baseline were small. Although the evidence suggested that golimumab may be less effective in its anti-arthritic activity (based on the HAQ score results from the mixed treatment comparison and the data for radiographic progression), on balance the Committee concluded that the evidence was not robust enough to confirm clinically important differences in the effectiveness of golimumab compared with the other TNF inhibitors.

4.10 The Committee considered the evidence on the adverse event rates associated with the use of golimumab. It noted a number of reported ‘serious’ adverse events, but understood that GO-REVEAL was not powered to detect statistically significant differences in adverse event outcomes. The Committee considered
the additional evidence submitted by the manufacturer on the long-term adverse event data for golimumab in people with psoriatic arthritis, and also for people with rheumatoid arthritis and ankylosing spondylitis. It concluded that although there remains uncertainty about golimumab’s long-term adverse event profile, it had not been shown to be different from that of other TNF inhibitors.

4.11 The Committee considered the economic model presented by the manufacturer. The Committee noted that the model assumed people continuing on therapy maintained their initial improvement in HAQ score. The Committee considered the utility estimates incorporated in the model, and noted that the utility formula was derived from the HAQ score change and the PASI response. The HAQ score change had a greater effect on utility than the PASI response did, indicating that the calculated utility benefit was driven more by the reduction in joint symptoms than the reduction in skin disease. The Committee concluded that this was appropriate (see section 4.9).

4.12 The Committee considered the results of the manufacturer’s base-case analysis, which compared each of the TNF inhibitors (including golimumab) with palliative care. The Committee heard from the ERG that the pair-wise comparisons with palliative care needed to be reworked into an incremental analysis comparing each treatment with the next most effective alternative. The ERG re-presented these results. The Committee was aware that the acquisition costs of adalimumab, etanercept and golimumab (50 mg) were similar, and that the acquisition cost of infliximab was dependent on the person’s weight and the amount of the drug required, with additional administration costs for infliximab (related to intravenous infusion). The Committee noted that all alternatives to etanercept were either dominated (infliximab was more expensive but no better than etanercept) or extendedly dominated
(adalimumab and golimumab were, in effect, less cost effective than etanercept; see section 3.20). The Committee agreed that golimumab was, in effect, less cost effective than etanercept.

4.13 The Committee was aware, however, that TA199 recommends adalimumab and infliximab alongside etanercept. The Committee therefore also considered whether golimumab was at least as cost effective as adalimumab and infliximab. The Committee was aware that in the incremental analysis, both adalimumab and golimumab were extendedly dominated by etanercept. However, the Committee noted that the pairwise ICER of golimumab compared with adalimumab alone would be approximately £24,000 per QALY gained. The Committee similarly noted that the pairwise ICER for golimumab compared with infliximab would be approximately £45,000, aware that in this instance the ICER would represent a ‘savings per QALY lost’, as golimumab was associated with both lower costs and fewer QALYs compared with infliximab (see section 3.19). Given the weaknesses of the evidence suggesting lesser clinical effectiveness of golimumab compared with the other TNF inhibitors, and the estimates of golimumab’s cost effectiveness compared with adalimumab and infliximab, the Committee concluded that the 50 mg dose of golimumab was acceptable when the criteria in TA199 are met; that is, the person has peripheral arthritis with three or more tender joints and three or more swollen joints, and the psoriatic arthritis has not responded to adequate trials of at least two standard disease-modifying antirheumatic drugs (DMARDs), administered either individually or in combination.

4.14 The Committee considered the 100 mg dose of golimumab. The Committee was aware that the SPC for golimumab states that for people who weigh more than 100 kg whose disease does not show an adequate clinical response after three or four doses, the dose of golimumab may be increased to 100 mg once a month. The
Committee heard two different opinions about the proportion of people who would be eligible for the higher dose. The Committee agreed that this proportion was uncertain, but that it could be substantial. The Committee noted that the 100 mg dose of golimumab was not considered in the economic model, but that, because of the patient access scheme (as described in section 2.4), the cost of the 100 mg dose would be equal to that of the 50 mg dose. In addition, the Committee acknowledged the comments from the clinical specialists that, in clinical practice, people would be more likely to be switched to a different TNF inhibitor if no response was observed with the 50 mg dose, than to have the dose increased (see section 4.6). The Committee also noted TA199 states that treatment choice should be based on cost (taking into account drug administration costs, required dose and product price per dose), with treatment initiated with the least expensive drug. Therefore the Committee concluded that with the incorporation of the patient access scheme, golimumab would be considered an acceptable option for the treatment of psoriatic arthritis if used as described for other TNF inhibitors in TA199.

4.15 The Committee discussed the discontinuation of treatment with etanercept, infliximab and adalimumab in TA199. The Committee considered that the recommendation to discontinue treatment based on an inadequate PsARC response at 12 weeks included in TA199 was also appropriate for golimumab. The Committee was aware that no evidence had been provided by the manufacturer for the use of golimumab after the failure of other TNF inhibitors. The Committee was therefore unable to make recommendations about the use of golimumab following the failure of other TNF inhibitors.

4.16 The Committee was aware that there may be some circumstances that could affect a person’s responses to components of the PsARC such as any physical, sensory or learning disabilities, or communication difficulties. The Committee concluded that in such
cases, healthcare professionals should make any adjustments they consider appropriate.

4.17 The Committee was aware of registries that collect data on the long-term outcomes of treatment with TNF inhibitors for rheumatoid arthritis. The Committee noted the importance of registries in gathering data and supported the inclusion of outcomes specific to psoriatic arthritis in a suitable registry so that specific information about treatments and treatment-related adverse events in psoriatic arthritis can be collected.

4.18 In summary, the Committee considered the clinical and cost effectiveness of golimumab in the light of the submitted evidence and the comments of the clinical specialists, the commissioning expert and the patient expert. The Committee noted that although the evidence suggested that golimumab may be less effective in its anti-arthritic activity (based on the HAQ score results from the mixed treatment comparison and the data for radiographic progression), the evidence was not robust enough to confirm clinically important differences in the effectiveness of golimumab compared with the other TNF inhibitors. The Committee further noted that golimumab was, in effect, not cost effective when compared with etanercept, but may be cost effective when compared with adalimumab and infliximab. The Committee was aware that the patient access scheme (as described in section 2.4) would provide the 100 mg dose of golimumab at the same cost as the 50 mg dose. The Committee concluded that, with the incorporation of the patient access scheme and if the criteria specified in TA199 were met, golimumab should be recommended as an option for the treatment of active and progressive psoriatic arthritis in adults, as described for other TNF inhibitor treatments in TA199.
Summary of the Appraisal Committee’s key conclusions

<table>
<thead>
<tr>
<th>TA220 (STA)</th>
<th>Golimumab for the treatment of psoriatic arthritis</th>
<th>FAD section</th>
</tr>
</thead>
<tbody>
<tr>
<td>Key conclusions</td>
<td></td>
<td>1.1</td>
</tr>
<tr>
<td>Golimumab is recommended as an option for the treatment of active and progressive psoriatic arthritis in adults only if:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• it is used as described for other tumour necrosis factor (TNF) inhibitor treatments in ‘Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis’ (<a href="#">NICE technology appraisal guidance 199</a>)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>and</td>
<td></td>
<td>1.2</td>
</tr>
<tr>
<td>• the manufacturer provides the 100 mg dose of golimumab at the same cost as the 50 mg dose.</td>
<td></td>
<td>4.9</td>
</tr>
<tr>
<td>When using the Psoriatic Arthritis Response Criteria (PsARC; as set out in NICE technology appraisal guidance 199), healthcare professionals should take into account any physical, sensory or learning disabilities, or communication difficulties that could affect a person’s responses to components of the PsARC and make any adjustments they consider appropriate.</td>
<td></td>
<td>4.13</td>
</tr>
<tr>
<td>The key drivers for these recommendations were:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• that the evidence was not robust enough to confirm clinically important differences in the effectiveness of golimumab compared with the other TNF inhibitors recommended in NICE technology appraisal guidance 199</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• that although golimumab was not as cost effective as etanercept, the cost-effectiveness estimates of the 50 mg dose of golimumab compared with adalimumab and infliximab were acceptable.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Current practice</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical need of patients</td>
<td>Psoriatic arthritis can cause significant distress and psychological impact on the person’s life. People with psoriatic arthritis value a choice among treatments, and may prefer the option of a treatment that is self-injectable and/or has a longer retreatment interval. The Committee noted that the pain and disability of the arthritis component of the disease often have a significant impact on the person’s quality of life.</td>
</tr>
<tr>
<td></td>
<td>4.9</td>
</tr>
</tbody>
</table>
### Availability of alternative treatments

NICE technology appraisal guidance 199 recommends adalimumab, etanercept and infliximab for the treatment of psoriatic arthritis when the person has peripheral arthritis with three or more tender joints and three or more swollen joints, and when the psoriatic arthritis has not responded to adequate trials of at least two standard DMARDs (administered either individually or in combination). NICE technology appraisal guidance 199 specifies that treatment should be with the least expensive drug, taking into account drug administration costs, required dose and product price per dose.

### The technology

#### Proposed benefits of the technology

How innovative is the technology in its potential to make a significant and substantial impact on health-related benefits and how it might improve the way that current need is met (i.e., is this a ‘step-change’ in the management of the condition)?

Clinical specialists and the patient expert emphasised that people often prefer a less frequent dosing schedule. The Committee understood that people with psoriatic arthritis and clinicians may therefore value the once-monthly, self-injectable administration of golimumab.

#### What is the position of the treatment in the pathway of care for the condition?

The Committee concluded that adalimumab, etanercept and infliximab as recommended in NICE technology appraisal guidance 199 were the appropriate comparators for golimumab.

#### Adverse effects

There were a number of ‘serious’ adverse events reported with the use of golimumab. However, the pivotal trial was not powered to detect statistically significant differences in adverse event outcomes. The Committee concluded that although there remains uncertainty about golimumab’s long-term adverse event profile, it had not been shown to be different from that of other TNF inhibitors.
## Evidence for clinical effectiveness

| Availability, nature and quality of evidence | The main clinical effectiveness data were derived from a single phase III RCT. The Committee noted statistically significant outcomes for the 50 mg dose of golimumab compared with placebo for improvements in joint disease, skin disease and functional status. The Committee concluded that golimumab was clinically effective compared with placebo. The Committee noted there had been no head-to-head trials between golimumab and any of the other TNF inhibitors. As a result, the manufacturer had conducted a mixed treatment comparison. The Committee recognised the limitations of mixed treatment comparisons and was aware that the associated results would need to be interpreted with caution. The Committee noted that for PsARC response and absolute change in PASI from baseline, the results of the mixed treatment comparison suggested golimumab was generally equivalent to the other TNF inhibitors. However, the Committee also noted that golimumab had the lowest HAQ score change from baseline compared with the other TNF inhibitors. The Committee was concerned that, out of the four TNF inhibitors that were compared, golimumab had the lowest HAQ score change from baseline and that this might indicate inferiority of its anti-arthritic activity; however, the Committee was also aware of the limitations of the mixed treatment comparison methodology. With regard to the data for radiographic progression, no mixed treatment comparison had been provided. Using a raw comparison of data from separate trials, the Committee understood that absolute differences between golimumab and infliximab in the respective change from baseline in vdh-S score were small, and may be due to differences in the trial populations. | 4.5 4.7 4.8 4.9 |
| Relevance to general clinical practice in the NHS | Clinical specialists stated that they would be more likely to select a different TNF inhibitor than to increase the dose if the 50 mg dose of golimumab failed to produce a response. | 4.6 |
Uncertainties generated by the evidence

| The main clinical trial evidence was derived from a single phase III, randomised controlled study. Because there had been no head-to-head trials between golimumab and any of the other TNF inhibitors, the manufacturer had conducted a mixed treatment comparison. Based on a raw comparison of golimumab trial data with that of infliximab, the change from baseline in vdB-H-S score (which is a measure of radiographic progression) at week 24 for golimumab was less than that for infliximab. The Committee was aware, however, that this difference may be due to differences in the trial populations, as reflected by the difference between the trials in the respective changes from baseline with placebo. The 100 mg dose in the pivotal trial was not limited to people weighing over 100 kg, and was therefore not reflective of the population in the marketing authorisation for that dose. | 4.7 |
| Are there any clinically relevant subgroups for which there is evidence of differential effectiveness? | No subgroups were identified for which there is evidence of differential effectiveness. | N/A |
| Estimate of the size of the clinical effectiveness including strength of supporting evidence | Although the evidence suggested that golimumab may be less effective in its anti-arthritic activity (based on the HAQ score results from the mixed treatment comparison and the data for radiographic progression), on balance the Committee concluded that the evidence was not robust enough to confirm clinically important differences in the effectiveness of golimumab compared with the other TNF inhibitors. | 4.9 |

Evidence for cost effectiveness

<p>| Availability and nature of evidence | The Committee heard from the ERG that the pairwise comparisons of each of the TNF inhibitors with palliative care needed to be reworked into an incremental analysis, comparing each treatment with the next most effective alternative. The ERG re-presented these results. | 4.12 |
| Uncertainties around and plausibility of assumptions and inputs in the economic model | The Committee noted that the 100 mg dose of golimumab was not considered in the economic model, but that, because of the patient access scheme (as described in section 2.4), the cost of the 100 mg dose of golimumab would be equal to that of the 50 mg dose. | 4.14 |</p>
<table>
<thead>
<tr>
<th><strong>Incorporation of health-related quality of life benefits and utility values</strong></th>
<th>The utility formula was derived from the HAQ score change and the PASI response. The HAQ score change had a greater effect on utility than the PASI response did, indicating that the utility benefit was driven more by the reduction in joint symptoms than the reduction in skin disease. The Committee concluded that this was appropriate.</th>
<th>4.11</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Have any potential significant and substantial health-related benefits been identified that were not included in the QALY calculation, and how have these been separately evaluated and what is the impact (if any) on the judgement of the most plausible ICER?</strong></td>
<td>There were no material claims made by the manufacturer regarding any health-related benefits of the technology that were not included in the QALY calculation. None were identified or considered by the Committee.</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Are there specific groups of people for whom the technology is particularly cost effective?</strong></td>
<td>No subgroups were identified for whom golimumab is particularly cost effective.</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>What are the key drivers of cost effectiveness?</strong></td>
<td>When each TNF inhibitor was compared with the next most effective alternative, all alternatives to etanercept were either dominated (infliximab) or extendedly-dominated (adalimumab and golimumab). As NICE technology appraisal guidance 199 recommends adalimumab and infliximab alongside etanercept, the Committee considered whether golimumab was at least as cost effective as adalimumab and infliximab. The Committee noted the weaknesses of the evidence suggesting clinically important differences in the effectiveness of golimumab compared with the other TNF inhibitors. Given the weaknesses of the evidence suggesting lesser clinical effectiveness of golimumab compared with the other TNF inhibitors, and the estimates of golimumab’s cost effectiveness compared with adalimumab and infliximab, the Committee concluded that the 50 mg dose of golimumab was acceptable when the criteria in NICE technology appraisal guidance 199 are met.</td>
<td>4.12</td>
</tr>
</tbody>
</table>

NICE technology appraisal guidance 220 26
<table>
<thead>
<tr>
<th>Most likely cost-effectiveness estimate (given as an ICER)</th>
<th>When each TNF inhibitor was compared with the next most effective alternative, all alternatives to etanercept were either dominated (infliximab) or extendedly-dominated (adalimumab and golimumab). The Committee concluded that golimumab was, in effect, less cost effective than etanercept. The ICER of golimumab compared with adalimumab alone would be approximately £24,000 per QALY gained. The ICER for golimumab compared with infliximab would be approximately £45,000, noting that in this instance the ICER would represent a ‘savings per QALY lost’, as golimumab was associated with both lower costs and fewer QALYs compared with infliximab.</th>
<th>4.12</th>
</tr>
</thead>
<tbody>
<tr>
<td>Additional factors taken into account</td>
<td>Patient Access Schemes (PPRS)</td>
<td>The manufacturer of golimumab has agreed a patient access scheme with the Department of Health, in which the 100 mg dose of golimumab will be available to the NHS at the same cost as the 50 mg dose. The Department of Health considered that this patient access scheme does not constitute an excessive administrative burden on the NHS.</td>
</tr>
<tr>
<td></td>
<td>End-of-life considerations (Supplementary advice on end-of-life)</td>
<td>The supplementary advice was not relevant to this appraisal.</td>
</tr>
<tr>
<td></td>
<td>Equalities considerations</td>
<td>The Committee concluded that, when using the PsARC, healthcare professionals should take into account any physical, sensory or learning disabilities, or communication difficulties that could affect a person’s responses to components of the PsARC and make any adjustments they consider appropriate.</td>
</tr>
</tbody>
</table>

5 Implementation

5.1 The Secretary of State and the Welsh Assembly Minister for Health and Social Services have issued directions to the NHS in England and Wales on implementing NICE technology appraisal guidance. When a NICE technology appraisal recommends use of a drug or treatment, or other technology, the NHS must usually provide funding and resources for it within 3 months of the guidance being issued.
published. If the Department of Health issues a variation to the 3-month funding direction, details will be available on the NICE website. When there is no NICE technology appraisal guidance on a drug, treatment or other technology, decisions on funding should be made locally.

5.2 NICE has developed tools to help organisations put this guidance into practice (listed below). These are available on our website (www.nice.org.uk/guidance/TA220).

- A costing statement explaining the resource impact of this guidance.
- Audit support for monitoring local practice.

6 Recommendation for further research

6.1 The Committee highlighted the importance of collecting further data within registries of patients receiving biological treatments for psoriatic arthritis to obtain information on long-term outcomes, including adverse events.

7 Related NICE guidance

8 Review of guidance

8.1 The guidance on this technology will be considered for review by the Guidance Executive alongside NICE technology appraisal guidance 199 (‘Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis’, review date June 2013). The Guidance Executive will decide whether the technology should be reviewed based on information gathered by NICE, and in consultation with consultees and commentators.

Andrew Dillon
Chief Executive
April 2011
Appendix A: Appraisal Committee members and NICE project team

A Appraisal Committee members

The Appraisal Committees are standing advisory committees of NICE. Members are appointed for a 3-year term. A list of the Committee members who took part in the discussions for this appraisal appears below. There are four Appraisal Committees, each with a chair and vice chair. Each Appraisal Committee meets once a month, except in December when there are no meetings. Each Committee considers its own list of technologies, and ongoing topics are not moved between Committees.

Committee members are asked to declare any interests in the technology to be appraised. If it is considered there is a conflict of interest, the member is excluded from participating further in that appraisal.

The minutes of each Appraisal Committee meeting, which include the names of the members who attended and their declarations of interests, are posted on the NICE website.

Dr Kathryn Abel
Reader and Consultant Psychiatrist/Director of Centre for Women’s Mental Health, University of Manchester

Dr David Black
Director of Public Health, Derbyshire County Primary Care Trust

Dr Daniele Bryden
Consultant in Intensive Care Medicine and Anaesthesia, Sheffield Teaching Hospitals NHS Trust

Dr Andrew Burnett
Director for Health Improvement and Medical Director, NHS Barnet, London
Dr Mary Cooke
Lecturer, School of Nursing, Midwifery and Social Work, University of Manchester

Dr Chris Cooper
General Practitioner, London

Professor Peter Crome
Consultant Physician, Bucknall Hospital, Stoke-on-Trent

Dr Christine Davey
Senior Researcher, North Yorkshire Alliance Research and Development Unit, North Yorkshire

Richard Devereaux-Phillips
Public Affairs and Reimbursement Manager UK and Ireland, Medtronic, Watford

Professor Rachel A Elliott
Lord Trent Professor of Medicines and Health, University of Nottingham

Dr Wasim Hanif
Consultant Physician and Honorary Senior Lecturer, University Hospital Birmingham

Professor Cathy Jackson
Professor of Primary Care Medicine, University of St Andrews

Dr Peter Jackson
Clinical Pharmacologist, University of Sheffield

Professor Gary McVeigh
Professor of Cardiovascular Medicine, Queens University Belfast and Consultant Physician, Belfast City Hospital

Dr Eugene Milne
Deputy Medical Director, North East Strategic Health Authority, Newcastle upon Tyne

Dr Neil Myers
General Practitioner, Glasgow
Dr Richard Nakielny
Consultant Radiologist, Sheffield Teaching Hospitals Foundation Trust

Dr Katherine Payne
Health Economics Research Fellow, University of Manchester

Dr Danielle Preedy
Lay member

Dr Peter Selby
Consultant Physician, Central Manchester University Hospitals NHS Foundation Trust

Ellen Rule
Programme Director, NHS Bristol

Dr Peter Selby
Consultant Physician, Central Manchester University Hospitals NHS Foundation Trust

Dr Surinder Sethi
Consultant in Public Health Medicine, North West Specialised Services Commissioning Team, Warrington

Professor Andrew Stevens
Chair of Appraisal Committee C, Professor of Public Health, University of Birmingham

Dr Matt Stevenson
Reader in Health Technology Assessment, School of Health and Related Research, University of Sheffield

Professor Paul Trueman
Health Economics Research Group, Brunel University

Dr Judith Wardle
Lay member
C NICE project team

Each technology appraisal is assigned to a team consisting of one or more health technology analysts (who act as technical leads for the appraisal), a technical adviser and a project manager.

Whitney Miller
Technical Lead

Helen Knight
Technical Adviser

Lori Farrar
Project Manager
Appendix B: Sources of evidence considered by the Committee

A  The Evidence Review Group (ERG) report for this appraisal was prepared by the NHS Centre for Reviews and Dissemination and Centre for Health Economics:


B  The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to give their expert views. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

I  Manufacturer/sponsor:

- Centocor/Schering-Plough

II  Professional/specialist and patient/carer groups:

- Psoriasis and Psoriatic Arthritis Alliance
- Psoriasis Association
- British Association of Dermatologists
- British Health Professionals in Rheumatology
- British Society for Rheumatology
- Primary Care Rheumatology Society
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians

III Other consultees:

- Department of Health
- NHS Haringey
- NHS Havering
- Welsh Assembly Government

IV Commentator organisations (did not provide written evidence and without the right of appeal):

- British National Formulary
- Commissioning Support Appraisals Service
- Department of Health, Social Services and Public Safety for Northern Ireland
- NHS Quality Improvement Scotland
- Abbott (adalimumab)
- Pfizer (methotrexate, sulfasalazine)
- Sanofi-Aventis (leflunomide)
- National Institute for Health Research Health Technology Assessment Programme
- NHS Centre for Reviews & Dissemination and Centre for Health Economics – York

C The following individuals were selected from clinical specialist and patient expert nominations from the non-manufacturer/sponsor consultees and commentators. They gave their expert personal view on golimumab for the treatment of psoriatic arthritis by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD.

- Eleanor Korendowych, Consultant Rheumatologist, nominated by British Society for Rheumatology – clinical specialist
• Alex Anstey, Consultant Dermatologist, nominated by British Association of Dermatologists – clinical specialist
• Philip Helliwell, nominated by British Society of Rheumatology – clinical specialist
• Jana James, nominated by Psoriasis and Psoriatic Arthritis Alliance – patient expert

D The following individual was nominated as NHS Commissioning expert by the selected NHS trust allocated to this appraisal. She gave her NHS commissioning personal view on golimumab for the treatment of psoriatic arthritis by attending the initial Committee discussion and providing written evidence to the Committee. She was also invited to comment on the ACD.

• Sue Ashwell, Chief Pharmacist, NHS Cambridgeshire selected by NHS Havering – NHS Commissioning expert

E Representatives from the following manufacturer/sponsor attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy:

• Merck Sharp & Dohme (formerly Schering-Plough)